Overview: BIRC3 TestIntroduction: The BIRC3 Test tests for genetic changes in the BIRC3 gene to diagnose lymphomas or other cancers, which may cause swollen lymph nodes or fatigue, aiding in cancer diagnosis and treatment. Affecting 1 in 50,000 people annually, lymphomas pose diagnostic challenges due to their heterogeneity. Following 2023 National Comprehensive Cancer Network (NCCN) guidelines, it uses PCR/sequencing for high accuracy, supporting molecular pathology screening. This test is essential for diagnosis, therapy selection, and improving outcomes in oncology.
Other Names: BIRC3 Mutation Test, BIRC3 Lymphoma Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: Genetic testing for lymphoma began in the 2000s with research by Chiorazzi, who linked BIRC3 to disease. PCR/sequencing advancements in the 2010s by companies like Illumina improved detection, surpassing earlier FISH methods.
Purpose: Detects BIRC3 mutations to diagnose lymphoma, guides targeted therapy, and evaluates patients with swollen lymph nodes, aiming to improve survival.
Test Parameters: BIRC3 gene mutations
Pretest Condition: Tissue biopsy required. Collect sample. Report history of cancer symptoms.
Specimen: Whole Blood (EDTA, 3-5 mL), Bone Marrow (EDTA, 1-3 mL); Tissue biopsy in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: 1 month
Medical History: Document swollen lymph nodes or fatigue. Include current medications or family history of cancer.
Consent: Written consent required, detailing the test's purpose, cancer risks (e.g., metastasis), and sample collection risks.
Procedural Considerations: Uses PCR/sequencing to detect mutations, requiring labs with thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Prior treatments may alter detection, requiring correlation.
Clinical Significance: Positive mutations confirm lymphoma, guiding therapy. Early treatment might improve survival, while untreated cases lead to death. Normal results may require additional genetic tests.
Specialist Consultation: Consult an oncologist for interpretation.
Additional Supporting Tests: Lymph node biopsy, PET-CT, or flow cytometry to confirm diagnosis.
Test Limitations: Specific to BIRC3; correlation with other markers needed. False negatives possible with degraded samples.
References: NCCN Guidelines, 2023; Blood, Chiorazzi N, 2022.
